MENLO PARK, Calif. & TORONTO--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) and Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that the companies have entered into an agreement that provides Biovail with access to Depomed’s proprietary AcuForm™ drug delivery technology for the development of up to two Biovail products.
